Day 1 :
Keynote Forum
Magdy El-Salhy
Professor of Gastroenterology and Hepatology
Keynote: Intestinal endocrine cells as biomarkers for the diagnosis of irritable bowel syndrome
Biography:
Magdy El-Salhy is Professor of Gastroenterology and Hepatology at Bergen University, and Consultant Gastroenterologist at Stord Hospital, Norway. He is a\r\nMember of the Editorial Boards of 10 international journals, and is associated Editor-in-Chief of World Journal of Gastroenterology. Furthermore, he is on the\r\nreferee list of a large number of international journals. He has evaluated grant applications for national and international research foundations. He has also attended\r\nand contributed to several national and international meetings as Invited Speaker, or Chairman. He authored over 200 publications, which include original articles,\r\ninvited reviews, book chapters, and books. His work has been cited in 4105 scientific articles. In 2013-2015, four of his highly cited papers are in the top 1% of world\r\npublications. His research field for the last 40 years has been the neuroendocrine system of the gut, from basic science to clinical applications.
Abstract:
The diagnosis of Irritable Bowel Syndrome (IBS) in clinical practice is a diagnosis of exclusion, whereby diagnostic tests\r\nand invasive investigations are conducted to exclude other gastrointestinal diseases. Attempts have been made to achieve\r\na positive diagnosis based on symptoms assessment such as the Rome III criteria. However, symptom-based diagnosis is not\r\nwidely used in everyday clinical practice. Searches for biomarkers for the diagnosis of IBS that reflect pathological states have\r\nnot yielded any useful candidates. The duodenum contains the largest number of endocrine cells in the gastrointestinal tract,\r\nfollowed by the rectum. The densities of four of the five duodenal endocrine cell types have been found to be reduced in patients\r\nwith sporadic (non-specific) IBS. Chromogranin A (CgA) is a common marker for gastrointestinal endocrine cells. It has been\r\nthought that the cell density of CgA the duodenal endocrine cells, can be used as a biomarker for the diagnosis of IBS. Receiver\r\nOperator Characteristic (ROC) revealed areas under the ROC curve (ROCAUC) values of 0.97, and positive likelihood (+LH)\r\nand negative LR (-LH) of 18.5 and 0.14, respectively. This biomarker is simple, inexpensive, and easy to perform, and does not\r\nrequire sophisticated equipment or considerable experience. The density of PYY cells is reduced in the rectum of sporadic IBS\r\npatients, whereas that of somatostatin is increased. As biomarkers for the diagnosis of IBS, rectal PYY has a ROCAUC values\r\nof 0.96 and +LH and –LH 7.56 and 0.18, respectively. The corresponding values for somatostatin are 0.93, 7.20, and 0.23. These\r\nbiomarkers erform well in differentiating IBS from health and are better than Rome III criteria, which has +LH and –LH of\r\n3.53 and 0.39, respectively. Moreover, these biomarkers reflect an anatomical lesions occurring in the gastrointestinal tract of\r\nIBS patients, namely gastrointestinal endocrine cells.
Keynote Forum
Rajendra Sharma
Medical Doctor, Tutor in Department of pharmacology
Keynote: Effect of Vitamin D supplementation in patients of moderate asthma undergoing treatment with inhaled corticosteroids
Biography:
Rajendra Sharma is a Medical Doctor who hails from Uttarakhand. He is a keen research Worker and is having his interest in learning further about newer\r\ndevelopment in pharmaceutical sciences. He has worked with pharmaceutical organization in different settings like clinical research, pharmacovigilance and\r\nproduct development before joining Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Jolly Grant, Dehradun. He is currently a Tutor in\r\nDepartment of pharmacology, Himalayan Institute of Medical Sciences, Dehradun
Abstract:
Background: Vitamin D is an essential nutrient with significant immuno-modulatory effects. There is potential for a protective\r\nrole of vitamin D against etiopathogenesis of asthma and morbidity. This study evaluated the effect of vitamin D supplementation\r\nin patients with moderate asthma.\r\nAims & Objectives: To evaluate the effect of vitamin D supplementation on lung function improvement in patients of moderate\r\nasthma undergoing treatment with inhaled corticosteroids.\r\nMaterial & Methods: An interventional prospective study. A total of 60 patients of moderate asthma were enrolled in the study\r\nand randomly divided into two groups of 30 patients each. Group A: placed on steroid based treatment regimen (formoterol\r\n6 μg+budesonide 200 μg)+Vitamin D supplementation [60,000 IU/week for 8 consecutive weeks]. Group B: placed on steroid\r\nbased treatment regimen (formoterol 6 μg+budesonide 200 μg) only, as control. The enrolled patients were followed up for\r\n12 weeks and assessed for various parameters of disease severity, asthma control and improvement in lung function by using\r\nAsthma Control Test [ACT] questionnaire and pulmonary function tests (spirometry). Collected data was analyzed using\r\navailable statistical software [spss ver 20.0].\r\nResults: Statistically significant changes were seen in pre to post values of FEV1 [2.29±0.41 to 2.64±0.52], FVC [3.37±0.74\r\nto 3.61±0.76] and FEV1/FVC ratio [68.44±5.04 to 73.49±3.52] in Group A as well as in Group B, i.e., FEV1 [2.28±0.48 to\r\n2.65±0.53], FVC [3.36±0.68 to 3.58±0.76] and FEV1/FVC ratio [67.88±2.48 to 74.16±4.19]. However, there were no significant\r\ndifferences observed in pre and post values of FEV1, FVC and FEV1/FVC ratio in between the two groups.\r\nConclusion: Vitamin D supplementation failed to show additional benefits in lung function improvement in adults with\r\nmoderate asthma undergoing treatment with inhaled corticosteroids in the present study.
Keynote Forum
Sabyasachi Sarkar
Professor Emeritus at IIESTS
Keynote: Nano carbons cross blood brain barrier with potential to entrap and release Alzheimer drug and other relevant molecules
Biography:
Sabyasachi Sarkar is presently Honorary Professor Emeritus at IIESTS, West Bengal and was Senior Professor and Former Head, Chemistry Department of IIT\r\nKanpur where he served 34 years. His research of 48 years spans in the diversified fields on the modeling of the metalloproteins originated from the chemical\r\nDarwinism of the extant life. He has guided over 40 PhD, and more than 150 MSc and MTech students in their research, published more than 200 publications and\r\nfour US and Indian patents. He is an Alexander von Humboldt Fellow (Germany), INSA Research Fellow (New Delhi), Raja Ramanna Fellow (DST, New Delhi),\r\nDAAD Fellow (Germany), and Fellow of the Indian Chemical Society (Kolkata), Fellow of the Indian Academy of Sciences (Bangalore) and Fellow of the Royal\r\nSociety of Chemistry (UK).
Abstract:
Water soluble Carbon Nano Onions (wsCNO) (25-50 nm) are used to image the life cycle of Drosophila melanogaster.\r\nThe multi-layered wsCNO may be used in drug delivery. The Blood–Brain Barrier (BBB) regulates brain homeostasis\r\nand selectively permits the entry of necessary molecules to pass into the brain through tight junctions and enzymatic carriers.\r\nThis BBB is the greatest impediment preventing any diagnostic or therapeutic probe in combating neuronal disorders or the\r\ngrowth of a tumor inside the brain. Fluorescent wsCNO may be used as a Trojan horse to carry the drug, the drug on its own\r\nis a foreign body, may be impermeable to the brain. We report here the crossing of wsCNO through the BBB in the murine\r\nmodel of CADASIL as well as in GBM induced mice. Donepezil, an inhibitor of acetylcholinesterase, is entrapped by wsCNO\r\nin acidic Phosphate Buffer Saline (PBS) demonstrating its function as Trojan horse from which the drug is readily released\r\nat pH 7.4. The action of wsCNO as Trojan horse is due to its physiological pH dependent ‘open and closed sesame’ behavior\r\nwhere the spherical wsCNO opens its shape as flat sheet to engulf the drug and closing it. This lecture will also present that\r\nseveral relevant large molecules like tetraphenylporphyrin or ferromagnetic mixed iron oxide can be entrapped and released\r\nsimilarly using graphene oxide prepared by a simple low cost method in the size range 40-200 nm as drug cargo under similar\r\npH dependent action.
Keynote Forum
Kailash Chandra Gupta
Professor
Keynote: Role of natural and functional polymers in drug delivery systems
Time : 12:05-12:35
Biography:
Gupta obtained D.Phil. Degree in Chemistry from University of Allahabad in 1984 on Polymer Chemistry and has been awarded fellowships by Govt. of France,rnUSSR, Denmark, Poland and Japan under cultural exchange programs of Govt. of India. Prof. Gupta worked as Scientist at IIT. New Delhi and then moved to IIT.rnRoorkee as Lecturer in 1987 and now working as Professor since 2004. Gupta has published more than 100 research articles in International Journals of PolymerrnScience and actively engaged in guiding PhD and M.Tech students from various streams. He has also supervised research projects funded by DST, CSIR, UGCrnand AICTE, New Delhi, India. Gupta served as member on editorial board of National and International Journals of Polymers and Chemistry. He is a member ofrnseveral International Scientific Societies including American Chemical Society, Washington and USA.
Abstract:
Functional and smart polymers are currently playing a significant role in formulations of controlled drug delivery systems duernto their responsive behavior towards environmental stimuli. The delivery systems must be non-toxic, non-immunogenicrnand must be having optimum trapping and release properties for an active agent. To be more effective and economical therncontrolled devices should be able to release active agent in a control and site-specific manner. The physical and chemicalrnproperties of the polymers provide opportunities to design therapeutic devices for various applications. Though variousrndelivery systems based on electrical, mechanical and viral systems have been fabricated with great successes but these deliveryrnsystems have shown poor transfection efficiency and found to be immunogenic; hence delivery systems based on functionalrnpolymers such as poly (ethylene glycol) and dendric poly (amidoamine) found to be of great significance. The delivery systemsrnusing natural and biodegradable polymers such as chitosan, pectin and polysaccharides proved to be more are acceptable duernto their biocompatibility and biodegradability in physiological fluids in comparison to synthetic polymer systems. Consideringrnthe importance of natural polymers, the pH and ion responsive drug delivery systems have been designed using different formsrnand derivatives of the chitosan. These delivery systems have been tested for efficiency of loading and delivery of active agentsrnas a function of solution pH and ionic strength of the medium. The naturally occurring chitosan has provided enormousrnopportunities for controlling its properties to fabricate control site specific delivery systems. The degree of deacetylation inrnchitosan proved to be significant in controlling its stimuli responsive properties for drug delivery systems. The nano sizedrnchitosan delivery systems found to be more therapeutic in comparison to macro and micro sized delivery devices for controlledrnand sustained delivery of the active agents. The role of various parameters would be discussed and highlighted in this talk.
Keynote Forum
Wolfgang Lechner
CEO of different pharmacies in Austria and is now the Owner of a provincial pharmacy.
Keynote: Hospital-pharmacie, Compatibility of active components in parenteral infusions
Time : 10:30-10:45
Biography:
Wolfgang Lechner has completed his studies for pharmacy and has been promoted as Mag. Pharm. at Karl-Franzens Universität in 1985 and continued with PostdoctoralrnResearch in a pharmaceutical laboratory of the same university with HPLC (High Pressure Liquid Chromatography). He was CEO of different pharmacies in Austria and isrnnow the Owner of a provincial pharmacy.
Abstract:
Parenteral medication today is standard procedure in clinical therapy not only in hospitals but also in the ambulant and practicalrnsector. Extremely important is this kind of application for intensive care because it is the only way to provide medication andrnnutrition. Frequently, physicians and care personnel are not aware that drugs strongly differ in pH-value and solubility and arbitraryrnmixing can cause serious consequences and a worse outcome for the patients. Incompatibilities are unwanted physical-chemicalrnreactions of a drug with a solvent which take place before or during an application. These reactions are not to be mistaken as interactionsrnwhich change the effect of a drug by impact of another substance. Physical or “manifest†incompatibilities usually can be seen as arnchange of colour, separation, tarnish or precipitation caused by a change of proportion between ionisation and solubility. Chemical orrn“concealed†incompatibilities are characterized by chemical disintegration and macroscopically not recognizable. Analytical methodsrn(i.e., HPLC) have to be used. For a secure parenteral therapy critical or problematical situations have to be identified before thernapplication which is a major task for pharmacists with their widespread chemical-pharmaceutical knowledge. Our aim is to achieverna clearly arranged tool for the wards to enable the daily application of parenteral medication through central or peripheric-venousrncatheters in an easy and safe way.
Keynote Forum
Driekus Grooff
professor
Keynote: Kinetic parameters from thermally stimulated dehydration and the relationship to drug-water interactions in pharmaceutical hydrates
Time : 1221
Biography:
Driekus Grooff is currently Lecturer of physical chemistry at Nelson Mandela Metropolitan University, Port Elizabeth South Africa. He obtained his PhD in 2010 at North-WestrnUniversity, Potchefstroom, South Africa. His research focuses on solid-state properties and stabilities of pharmaceutical compounds. Collaborative research with the Centerrnof Excellence for Pharmaceutical Sciences at North-West University is currently ongoing. Research outputs in international journals such as Journal of PharmaceuticalrnSciences and Thermochimica Acta have emphasized various aspects of solid-state chemistry and include pharmaceutical technology, analytical and physical chemistry.
Abstract:
A variety of Active Pharmaceutical Ingredients (API’s) can exist as hydrate forms. The conditions that facilitate hydrate formationrninclude factors such as humidity exposure during storage, pharmaceutical processing and dosage forms capable of transferringrnwater to API. It is mainly the thermodynamic water activity of the surrounding medium (solution, vapour phase, etc.) thatrndetermines whether a given hydrate structure can be formed. Studies that evaluate hydrate structure and stability will be beneficialrnto the understanding of hydrate formation and influence on physico-chemical properties. Thermal analysis has been widely used forrncharacterization of pharmaceutical hydrates in terms of structural and stability investigations. For hydrate compounds the use ofrnThermo-Gravimetric (TG) analysis had explored both isothermal and non-isothermal heating regimes for the investigation of thermallyrnstimulated dehydration kinetic parameters. Knowledge of dehydration kinetic parameters under a controlled heating program offerrnunique insight to drug-water association as the kinetic information mostly relate to structural features and intermolecular forcesrnoperating with the parent anhydrate drug form. This study report findings of dehydration kinetic parameters from two structurallyrnrelates macrolide antibiotics in an attempt to correlate observed kinetic behaviour to the structural characterization of the hydraterncompounds.
Keynote Forum
Gannu Praveen Kumar
Professor,Principal in Sahasra Institute of Pharmaceutical Sciences
Keynote: The global strategies and innovations in the pharmaceutical industry
Time : 1221
Biography:
Gannu Praveen Kumar is a Professor and Principal in Sahasra Institute of Pharmaceutical Sciences since April 2014, graduated from H K E’s society college of Pharmacy,rnGulbarga University in 1997, Post-Graduation from BITS, Pilani in 1999 and PhD from UCPSC, Kakatiya University in 2009. He has published in both national andrninternational journals and compiled few chapters for text books. He received Gem of India award in the year 1999. He was selected as a Best Academician in 2001 andrn2011. He is an Advisor for few pharmaceutical companies. He visited foreign countries like London, Dubai, Singapore, Malaysia and Spain as Invited Speaker.
Abstract:
Continuous innovation is one of the pharmaceutical industry’s most defining characteristics. New medications can be crucial forrnmaintaining the quality of human life, and may even affect its duration. The global pharmaceutical market is expected to reachrn$1.1 trillion by 2015. Pharmaceutical innovation is marching towards an orderly, predictable process. It follows a technology pushrnmodel dependent on a meandering path of scientific breakthroughs with uneven timing and hard to foresee outcomes. Technologicalrncompetency, decades of rigorous research, and profound understanding of unmet customer needs, while necessary, may proverninsufficient for market success as the critical decision for commercialization remains outside the firm. Drug innovation as a businessrnprocess requires savvy strategic, organizational and managerial decisions. It is already enjoying intensive research coverage, givingrnrise to abundant but relatively dispersed knowledge of the mechanisms driving drug discovery and development. A comprehensivernoverview of the process of drug innovation from a business and academic perspective is explained. The evolving organizational formsrnand models for collaboration, summarize significant empirical regularities, and highlight differences in market positions related tornfirms’ strategic orientation, innovation emphasis, attitudes to risk, and specialized resources are highlighted. As a guide to futurernresearch, critical drivers and modes for drug innovation are systematized in a unifying framework of characteristics and processrndecisions, and multiple areas in need of further scrutiny, analysis, and optimization are suggested. Because of its rich potential andrnhigh significance, research on drug innovation seems poised to gain increasing momentum in the years to come.
Keynote Forum
Subham Banerjee
Keynote: Lipid Nanoparticle Formulations (LNFs): A holistic drug delivery strategy for improving oral bio-availability of Antitubercular Drugs (ATDs)
Time : 1221
Biography:
Subham Banerjee is designated as an Innovation Awardee in Devices, now pursuing his Post-Doctoral Research work at ID3S Laboratory, Center for Bio-design,rnTranslational Health Science and Technology (THSTI), Ministry of Science & Technology, Government of India, Faridabad, Haryana. Recently, he has completed his PhDrndegree from the joint collaboration of DRDO, Ministry of Defence, Government of India, Tezpur, Assam and BIT, Mesra Ranchi, Jharkhand. He has published more than 25rnpapers in a peer-reviewed journals, published one book chapter and filed two Indian patents. He is a Life-Time Member of India Science Congress Association
Abstract:
LNFs have emerged as potential drug carriers to improve Gastrointestinal (GI) absorption and oral bioavailability of severalrnATDs, especially lipophilic drug like rifampicin. These lipid based nanoformulations may also be used for sustained drug releasernof such ATDs. The two newer generations of LNFs, namely, Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriersrn(NLCs) having capability as oral drug carriers to improve poor and variable oral bioavailability, poor GI absorption, solubilityrnand chemical instability related several issues associated with ATDs that has been perceived as a major bottleneck in successfulrntreatment of Tuberculosis (TB). In these regard, LNFs based drug delivery strategy has been a boon to current pharmacology andrnbiopharmaceutical enhancement of drug performance. Moreover, it is possible to design lipid based drug delivery systems capable ofrntargeting phagocytic cells which are infected by intracellular pathogens, such as mycobacteria. LNFs based delivery systems based onrnnanotechnology offer wide opportunities for improving the therapy for a range of diseases including TB.
Keynote Forum
Monika Jadhav
Assistant Professor
Keynote: Implementation of Quality by Design approach to analytical method development and validation
Time : 1221
Biography:
Monika Jadhav has completed MPharm from Pune University and has a teaching experience of 2.5 years as Assistant Professor. She is currently working at Shri D DrnVispute College of Pharmacy & Research Center, Navi Mumbai. She has published 05 research articles from which 03 are international publications. And she is also onernof the Reviewer Board Members of International Journal of Pharmaceutical Chemistry and Analysis, Innovative Publication.
Abstract:
A QbD and lifecycle management approach to analytical method development and qualification results in a better understandingrnand fewer failures of analytical methods due to more robust methods which produce consistent, reliable, quality data throughoutrnthe lifecycle. This, in turn, leads to less method transfer failures and method “incidents†when used in the routine environment. Asrnthe MNC’s are now applying Quality by Design (QbD) to process development, it is now being recognized that this is also the wayrnforward to improve and standardize approach to analytical procedures. The recent focus within the pharmaceutical industry andrnassociated regulatory bodies on QbD approaches to analytical method development are a positive sign that both the industry andrnregulators are acknowledging the importance of understanding the contribution of measurement uncertainty to drug processes andrnproducts. The benefits of applying QbD principles to analytical methods include identifying and minimizing sources of variabilityrnthat may lead to poor method robustness and ensuring that the method meets its intended performance requirements throughoutrnthe product and method lifecycle. The ultimate goal is to highlight that QbD concepts and terminology can be applied to analyticalrnmethods and to suggest how adoption of a QbD approach might be used to develop more robust analytical methods and effectiverncontrol systems. At the same time, these efforts aim to support more advanced regulatory approaches to change management
Keynote Forum
Meha N Motiwala
Assistant Professor
Keynote: In vivo wound healing activity of Cajanus cajan on burn wound model in mice by regulating antioxidant and inflammatory mediators
Time : 1221
Biography:
M N Motiwala has completed her Master in Pharmacy (Pharmacognosy & Phytochemistry) from R T M Nagpur University in 2009. She has additional qualification asrnDiploma in Clinical Pharmacy and Diploma in Industrial Relation and Personnel Management. Presently, she is working as Assistant Professor at Dadasaheb BalpandernCollege of Pharmacy Besa, Nagpur, Maharashtra. She has published various articles in national and international journal. She has delivered oral presentation entitledrn“Effect of piperine on bioavailability of paclitaxel†at Current Drug Development International Conference, 2010, in Thailand.
Abstract:
The leaves of Cajanus cajan has been traditionally used by Indian village people in wound healing, jaundice, hypocholestrolemiarnand inflammation. The phytoconstituents of C. cajan includes flavonoids and stilbenes. Wound healing is a complex process thatrnincludes inflammation, tissue formation, and remodeling. In order to scientifically prove the claimed utilization of the plant, therneffects of the extracts were investigated using burn wound model in mice including in vivo antioxidant and antimicrobial activity.rnHealing was assessed by the rate of wound contraction, period of epithelization and hydroxyproline content. The antimicrobial activityrnof extract was also studied against bacterial and fungal strain using agar dilution method. In vivo antioxidant activity was performedrnto understand the mechanism of wound healing potency. The result showed that C. cajan leaf extract has significant wound healingrnactivity as evident from the rate of wound contraction and epithelization. Hydroxyproline content was correlative with the healingrnpattern observed. C. cajan leaf extract treatment promote up-regulation of pro-inflammatory cytokines TNF-α during early phase ofrnwound healing, inhibit ROS accumulation and exhibit moderate antimicrobial activity. We propose induction of cytokine productionrnas one of the mechanism for acceleration of wound healing by C. cajan leaf extract which may be due to flavonoids and stilbenes
Keynote Forum
Uma Devi P
Assistant Professor in the Department of Pharmacology
Keynote: Challenging clinical scenario of blood stream candida infections – An Indian experience
Time : 1121
Biography:
Uma Devi P has completed her Ph. D. in Pharmacology from Jamia Hamdard University, New Delhi. She has worked as Research Scientist at Ranbaxy LaboratoriesrnLimited, Gurgaon. Currently, she is working as Assistant Professor in the Department of Pharmacology, Amrita School of Pharmacy, Kochi. She has publishedrnpapers in reputed international journals.
Abstract:
Candida is an important cause of bloodstream infections (BSIs), causing significant mortality and morbidity. The truernburden of candidemia in India is not clear. Thus, this study was conducted to evaluate the clinical characteristics, speciesrndistribution, antifungal susceptibility and outcome of candidemia at our hospital. A total of 165 episodes of Candida BSI werernidentified between January 2012 and April 2014, with 115 episodes occurring in adult patients. Most of the episodes occurredrnin males (69.6%). Nearly 82.6% patients were between 41 to 80 years and majority of the patients were in the intensive carernunit (65.2%) at the time of diagnosis. Majority of the candidemia episodes were found in the general medicine departmentrn(23.5%) followed by gastrointestinal surgery (13.9%) and medical oncology & hematology (13%). Risk factors identifiedrnwere prior hospitalization within one year (83.5%), antibiotic therapy within the last one month (64.3%), indwelling urinaryrncatheter (63.5%), central venous catheter use (59.1%), diabetes mellitus (53%), severe sepsis (45.2%), mechanical ventilationrn(43.5%) and surgery (36.5%). C. tropicalis (30.4%) was the leading cause of infection followed by C. parapsilosis (28.7%) and C.rnalbicans (13%). Other non-albicans species isolated included C. haemulonii (7.8%), C. glabrata (7%), C. famata (4.3%) and C.rnkrusei (1.7%). Antifungal susceptibility to fluconazole was 87.9% (C. parapsilosis), 100% (C. tropicalis) and 93.3% (C. albicans).rnMortality was noted in 51 patients (44.3%). To conclude, rapid changes in the rate of infection, potential risk factors, andrnemergence of non-albicans Candida demand continued surveillance of this serious BSI.
- Pharmaceutics and Novel Drug Delivery Systems
Pharma Analytical Techniques and Instrumentation
Nanotechnology
Medicinal Chemistry and Drug Discovery
Session Introduction
Wolfgang Lechner
Karl-Franzens University, Austria
Title: Hospital-pharmacie: Compatibility of active components in parenteral infusions
Biography:
Wolfgang Lechner has completed his studies for pharmacy and has been promoted as Mag. Pharm. at Karl-Franzens Universität in 1985 and continued with Postdoctoral Research in a pharmaceutical laboratory of the same university with HPLC (High Pressure Liquid Chromatography). He was CEO of different pharmacies in Austria and is now the Owner of a provincial pharmacy.
Abstract:
Parenteral medication today is standard procedure in clinical therapy not only in hospitals but also in the ambulant and practical sector. Extremely important is this kind of application for intensive care because it is the only way to provide medication and nutrition. Frequently, physicians and care personnel are not aware that drugs strongly differ in pH-value and solubility and arbitrary mixing can cause serious consequences and a worse outcome for the patients. Incompatibilities are unwanted physical-chemical reactions of a drug with a solvent which take place before or during an application. These reactions are not to be mistaken as interactions which change the effect of a drug by impact of another substance. Physical or “manifest†incompatibilities usually can be seen as a change of colour, separation, tarnish or precipitation caused by a change of proportion between ionisation and solubility. Chemical or “concealed†incompatibilities are characterized by chemical disintegration and macroscopically not recognizable. Analytical methods (i.e., HPLC) have to be used. For a secure parenteral therapy critical or problematical situations have to be identified before the application which is a major task for pharmacists with their widespread chemical-pharmaceutical knowledge. Our aim is to achieve a clearly arranged tool for the wards to enable the daily application of parenteral medication through central or peripheric-venous catheters in an easy and safe way.
Bhubaneswar Mandal
Indian Institute of Technology Guwahati, India
Title: Novel and innovative strategies for peptide based drug design against Alzheimer’s disease
Biography:
Bhubaneswar Mandal has completed his PhD from EPFL, Lausanne, Switzerland under the supervision of Professor Manfred Mutter. Then he earned prestigious Marie Curie Fellowship and worked as a Post-Doctoral Fellow with Professor Herbert Waldmann and Professor Hans-Dieter Arndt, Max-Planck Institute for Molecular Physiology, Dortmund, Germany. Then he joined IIT Guwahati as an Assistant Professor. Presently, he is an Associate Professor there. He is working on novel strategy development for drug design against amyloidoses and industrially useful reagent development for various organic transformations. He has published 28 papers in reputed international journals.
Abstract:
Alzheimer’s Disease (AD), a common amyloidosis, has no cure yet. Pathological investigations revealed existence of numerous plaques in the Alzheimer’s patients’ brain composed of Amyloid-β (Aβ) peptides, derived from Amyloid Precursor Proteins (APPs). Although the mechanism of plaque formation is unknown, AD is believed to be caused by the aggregation of misfolded Aβ peptides. β-breaker peptides have been developed that disrupt amyloid aggregates (plaques) in vitro as well as in vivo. We have developed two novel and innovative strategies for β-breaker peptide design. First one is based on the concept of β-sheet breaker α/β hybrid peptides (BSBHps); and the second one on the concept of β-Breaker Di-Peptides (BBDPs). We have demonstrated that such well designed peptides are capable of inhibition of amyloid formation of Aβ peptide. Also, they disrupt preformed toxic fibrillar aggregates into non toxic species in vitro. Such peptides may be useful for designing novel drugs against diverse amyloidoses including Alzheimer’s disease, Parkinson’s disease and diabetes type II. Recent advancements in this direction of research will be discussed in the Pharma Summit-2015.
Nasimul Hoda
Jamia Millia Islamia, India
Title: Structure guided lead identification of potent Plasmodium falciparum phospho-ethanolamine methyltransferase inhibitors
Biography:
Nasimul Hoda has completed his PhD from Patna University and Postdoctoral studies from IIT Delhi, Supercomputing facility for bioinformatics and computational biology (SCFBIO-IITD). He is the Assistant Professor in Chemistry at Jamia Millia Islamia (Central University). He is working in the field of Drug design and focussing on the development of antimalarial and anti-neurodegenerative agents.
Abstract:
Malaria is a leading cause of human deaths affected by parasitic infection in tropical and subtropical reasons. Out of the four plasmodium species responsible for this disease in human Plasmodium falciparum is the most deadly. Due to the widespread resistance of the current antimalarial drugs, intense research efforts are focused on identification of new potent antimalarials. We report here, a structure based drug discovery strategy for design and synthesis of a series of potent and novel triazine based antimalarials. The X-ray structure of Plasmodium falciparum phosphoethanolamine methyltransferase (PfPMT) is used as a target as it is unique to the parasite. Trisubstituted triazine and its anlaogs are produced by an inexpensive three to four step synthesis giving excellent yields. Parasite growth inhibition assays further confirmed the activity of the molecules to be in 5 to 0.8 μM range showing selectivity towards the parasite over mammalian cells. Molecular dynamics simulations on the PfPMT-inhibitor complex shed light on the inhibition mechanism for further optimization of the lead compounds.
Driekus Grooff
Nelson Mandela Metropolitan University, South Africa
Title: Kinetic parameters from thermally stimulated dehydration and the relationship to drug-water interactions in pharmaceutical hydrates
Biography:
Driekus Grooff is currently Lecturer of physical chemistry at Nelson Mandela Metropolitan University, Port Elizabeth South Africa. He obtained his PhD in 2010 at North-West University, Potchefstroom, South Africa. His research focuses on solid-state properties and stabilities of pharmaceutical compounds. Collaborative research with the Center of Excellence for Pharmaceutical Sciences at North-West University is currently ongoing. Research outputs in international journals such as Journal of Pharmaceutical Sciences and Thermochimica Acta have emphasized various aspects of solid-state chemistry and include pharmaceutical technology, analytical and physical chemistry.
Abstract:
A variety of Active Pharmaceutical Ingredients (API’s) can exist as hydrate forms. The conditions that facilitate hydrate formation include factors such as humidity exposure during storage, pharmaceutical processing and dosage forms capable of transferring water to API. It is mainly the thermodynamic water activity of the surrounding medium (solution, vapour phase, etc.) that determines whether a given hydrate structure can be formed. Studies that evaluate hydrate structure and stability will be beneficial to the understanding of hydrate formation and influence on physico-chemical properties. Thermal analysis has been widely used for characterization of pharmaceutical hydrates in terms of structural and stability investigations. For hydrate compounds the use of Thermo-Gravimetric (TG) analysis had explored both isothermal and non-isothermal heating regimes for the investigation of thermally stimulated dehydration kinetic parameters. Knowledge of dehydration kinetic parameters under a controlled heating program offer unique insight to drug-water association as the kinetic information mostly relate to structural features and intermolecular forces operating with the parent anhydrate drug form. This study report findings of dehydration kinetic parameters from two structurally relates macrolide antibiotics in an attempt to correlate observed kinetic behaviour to the structural characterization of the hydrate compounds.
Gannu Praveen Kumar
Sahasra Institute of Pharmaceutical Sciences, India
Title: The global strategies and innovations in the pharmaceutical industry
Biography:
Gannu Praveen Kumar is a Professor and Principal in Sahasra Institute of Pharmaceutical Sciences since April 2014, graduated from H K E’s society college of Pharmacy, Gulbarga University in 1997, Post-Graduation from BITS, Pilani in 1999 and PhD from UCPSC, Kakatiya University in 2009. He has published in both national and international journals and compiled few chapters for text books. He received Gem of India award in the year 1999. He was selected as a Best Academician in 2001 and 2011. He is an Advisor for few pharmaceutical companies. He visited foreign countries like London, Dubai, Singapore, Malaysia and Spain as Invited Speaker.
Abstract:
Continuous innovation is one of the pharmaceutical industry’s most defining characteristics. New medications can be crucial for maintaining the quality of human life, and may even affect its duration. The global pharmaceutical market is expected to reach $1.1 trillion by 2015. Pharmaceutical innovation is marching towards an orderly, predictable process. It follows a technology push model dependent on a meandering path of scientific breakthroughs with uneven timing and hard to foresee outcomes. Technological competency, decades of rigorous research, and profound understanding of unmet customer needs, while necessary, may prove insufficient for market success as the critical decision for commercialization remains outside the firm. Drug innovation as a business process requires savvy strategic, organizational and managerial decisions. It is already enjoying intensive research coverage, giving rise to abundant but relatively dispersed knowledge of the mechanisms driving drug discovery and development. A comprehensive overview of the process of drug innovation from a business and academic perspective is explained. The evolving organizational forms and models for collaboration, summarize significant empirical regularities, and highlight differences in market positions related to firms’ strategic orientation, innovation emphasis, attitudes to risk, and specialized resources are highlighted. As a guide to future research, critical drivers and modes for drug innovation are systematized in a unifying framework of characteristics and process decisions, and multiple areas in need of further scrutiny, analysis, and optimization are suggested. Because of its rich potential and high significance, research on drug innovation seems poised to gain increasing momentum in the years to come.
Subham Banerjee
Translational Health Science & Technology Institute, India
Title: Lipid Nanoparticle Formulations (LNFs): A holistic drug delivery strategy for improving oral bioavailability of Antitubercular Drugs (ATDs)
Biography:
Subham Banerjee is designated as an Innovation Awardee in Devices, now pursuing his Post-Doctoral Research work at ID3S Laboratory, Center for Bio-design, Translational Health Science and Technology (THSTI), Ministry of Science & Technology, Government of India, Faridabad, Haryana. Recently, he has completed his PhD degree from the joint collaboration of DRDO, Ministry of Defence, Government of India, Tezpur, Assam and BIT, Mesra Ranchi, Jharkhand. He has published more than 25 papers in a peer-reviewed journals, published one book chapter and filed two Indian patents. He is a Life-Time Member of India Science Congress Association.
Abstract:
LNFs have emerged as potential drug carriers to improve Gastrointestinal (GI) absorption and oral bioavailability of several ATDs, especially lipophilic drug like rifampicin. These lipid based nanoformulations may also be used for sustained drug release of such ATDs. The two newer generations of LNFs, namely, Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) having capability as oral drug carriers to improve poor and variable oral bioavailability, poor GI absorption, solubility and chemical instability related several issues associated with ATDs that has been perceived as a major bottleneck in successful treatment of Tuberculosis (TB). In these regard, LNFs based drug delivery strategy has been a boon to current pharmacology and biopharmaceutical enhancement of drug performance. Moreover, it is possible to design lipid based drug delivery systems capable of targeting phagocytic cells which are infected by intracellular pathogens, such as mycobacteria. LNFs based delivery systems based on nanotechnology offer wide opportunities for improving the therapy for a range of diseases including TB.
Monika Jadhav
D D Vispute College of Pharmacy & Research Center, India
Title: Implementation of Quality by Design approach to analytical method development and validation
Biography:
Monika Jadhav has completed MPharm from Pune University and has a teaching experience of 2.5 years as Assistant Professor. She is currently working at Shri D D Vispute College of Pharmacy & Research Center, Navi Mumbai. She has published 05 research articles from which 03 are international publications. And she is also one of the Reviewer Board Members of International Journal of Pharmaceutical Chemistry and Analysis, Innovative Publication.
Abstract:
A QbD and lifecycle management approach to analytical method development and qualification results in a better understanding and fewer failures of analytical methods due to more robust methods which produce consistent, reliable, quality data throughout the lifecycle. This, in turn, leads to less method transfer failures and method “incidents†when used in the routine environment. As the MNC’s are now applying Quality by Design (QbD) to process development, it is now being recognized that this is also the way forward to improve and standardize approach to analytical procedures. The recent focus within the pharmaceutical industry and associated regulatory bodies on QbD approaches to analytical method development are a positive sign that both the industry and regulators are acknowledging the importance of understanding the contribution of measurement uncertainty to drug processes and products. The benefits of applying QbD principles to analytical methods include identifying and minimizing sources of variability that may lead to poor method robustness and ensuring that the method meets its intended performance requirements throughout the product and method lifecycle. The ultimate goal is to highlight that QbD concepts and terminology can be applied to analytical methods and to suggest how adoption of a QbD approach might be used to develop more robust analytical methods and effective control systems. At the same time, these efforts aim to support more advanced regulatory approaches to change management.
Meha N Motiwala
R T M Nagpur University, India
Title: In vivo wound healing activity of Cajanus cajan on burn wound model in mice by regulating antioxidant and inflammatory mediators
Biography:
M N Motiwala has completed her Master in Pharmacy (Pharmacognosy & Phytochemistry) from R T M Nagpur University in 2009. She has additional qualification as Diploma in Clinical Pharmacy and Diploma in Industrial Relation and Personnel Management. Presently, she is working as Assistant Professor at Dadasaheb Balpande College of Pharmacy Besa, Nagpur, Maharashtra. She has published various articles in national and international journal. She has delivered oral presentation entitled “Effect of piperine on bioavailability of paclitaxel†at Current Drug Development International Conference, 2010, in Thailand.
Abstract:
The leaves of Cajanus cajan has been traditionally used by Indian village people in wound healing, jaundice, hypocholestrolemia and inflammation. The phytoconstituents of C. cajan includes flavonoids and stilbenes. Wound healing is a complex process that includes inflammation, tissue formation, and remodeling. In order to scientifically prove the claimed utilization of the plant, the effects of the extracts were investigated using burn wound model in mice including in vivo antioxidant and antimicrobial activity. Healing was assessed by the rate of wound contraction, period of epithelization and hydroxyproline content. The antimicrobial activity of extract was also studied against bacterial and fungal strain using agar dilution method. In vivo antioxidant activity was performed to understand the mechanism of wound healing potency. The result showed that C. cajan leaf extract has significant wound healing activity as evident from the rate of wound contraction and epithelization. Hydroxyproline content was correlative with the healing pattern observed. C. cajan leaf extract treatment promote up-regulation of pro-inflammatory cytokines TNF-α during early phase of wound healing, inhibit ROS accumulation and exhibit moderate antimicrobial activity. We propose induction of cytokine production as one of the mechanism for acceleration of wound healing by C. cajan leaf extract which may be due to flavonoids and stilbenes.
Uma Devi P
Amrita Vishwa Vidyapeetham University, India
Title: Challenging clinical scenario of blood stream candida infections – An Indian experience
Biography:
Uma Devi P has completed her Ph. D. in Pharmacology from Jamia Hamdard University, New Delhi. She has worked as Research Scientist at Ranbaxy Laboratories Limited, Gurgaon. Currently, she is working as Assistant Professor in the Department of Pharmacology, Amrita School of Pharmacy, Kochi. She has published papers in reputed international journals.
Abstract:
Candida is an important cause of bloodstream infections (BSIs), causing significant mortality and morbidity. The true burden of candidemia in India is not clear. Thus, this study was conducted to evaluate the clinical characteristics, species distribution, antifungal susceptibility and outcome of candidemia at our hospital. A total of 165 episodes of Candida BSI were identified between January 2012 and April 2014, with 115 episodes occurring in adult patients. Most of the episodes occurred in males (69.6%). Nearly 82.6% patients were between 41 to 80 years and majority of the patients were in the intensive care unit (65.2%) at the time of diagnosis. Majority of the candidemia episodes were found in the general medicine department (23.5%) followed by gastrointestinal surgery (13.9%) and medical oncology & hematology (13%). Risk factors identified were prior hospitalization within one year (83.5%), antibiotic therapy within the last one month (64.3%), indwelling urinary catheter (63.5%), central venous catheter use (59.1%), diabetes mellitus (53%), severe sepsis (45.2%), mechanical ventilation (43.5%) and surgery (36.5%). C. tropicalis (30.4%) was the leading cause of infection followed by C. parapsilosis (28.7%) and C. albicans (13%). Other non-albicans species isolated included C. haemulonii (7.8%), C. glabrata (7%), C. famata (4.3%) and C. krusei (1.7%). Antifungal susceptibility to fluconazole was 87.9% (C. parapsilosis), 100% (C. tropicalis) and 93.3% (C. albicans). Mortality was noted in 51 patients (44.3%). To conclude, rapid changes in the rate of infection, potential risk factors, and emergence of non-albicans Candida demand continued surveillance of this serious BSI.